FDA Approves Toripalimab for Advanced Nasopharyngeal Cancer
Adding toripalimab (Loqtorzi) to chemo extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.
Related Articles
NCCR*Explorer Application
Use NCCR*Explorer to select data characteristics including cancer site, incidence or survival, sex, race/ethnicity, and age groups (0-39) to display incidence rates, trends over time,…
Cancer Prevention Overview
Cancer prevention methods include avoiding things that cause cancer, having a healthy lifestyle, getting screened, and using some medicines or surgery. Learn more about ways…
Enasidenib Monotherapy Shows Promise for Patients With IDH2-Mutated MDS | Blood Cancers Today
Preliminary findings from a phase II trial suggest that enasidenib offers clinically meaningful responses and a manageable safety profile in MDS.
Current Issue : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
H-E-B | Curbside Pickup & Grocery Delivery | HEB.com
No store does more than your H-E-B, where you’ll find savings on products you love, without compromise of convenience, quality or selection. Free Curbside!
American Cancer Society nutrition and physical activity guideline for cancer survivors
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
OCE Oncology News
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
Current Issue : Oncology Times
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma
This phase 2 nonrandomized clinical trial assesses the efficacy and safety of dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma.
